{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:40:43Z","timestamp":1765233643490,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001772","name":"University of New England","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001772","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod. Sci."],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To determine the relationships between luteal-phase steroidal hormonal profile and PMS for a large number of women attending a dedicated fertility clinic. This was a retrospective cross-sectional study on women attending a hospital-based clinic for fertility concerns and\/or recurrent miscarriage. All participants were assessed with a women\u2019s health questionnaire which also included evaluation of premenstrual symptoms. Day of ovulation was identified based on the peak mucus symptom assessed by the woman after instruction in a fertility awareness-based method (FABM). This enabled reliable timing of luteal-phase serum hormone levels to be taken and analysed. Between 2011 and 2021, 894 of the 2666 women undertaking the women\u2019s health assessment had at least one evaluable serum luteal hormone test. Serum progesterone levels were up to 10\u00a0nmol\/L lower for symptomatic women compared with asymptomatic women. This difference was statistically significant (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) for the majority of PMS symptoms at\u2009\u2265\u20099\u00a0days after the peak mucus symptom. A similar trend was observed for oestradiol but differences were generally not statistically significant. ROC curves demonstrated that steroid levels during the luteal phase were not discriminating in identifying the presence of PMS symptoms. Blood levels for progesterone were lower throughout the luteal phase in women with PMS, with the greatest effect seen late in the luteal phase.<\/jats:p>","DOI":"10.1007\/s43032-023-01375-w","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T16:03:24Z","timestamp":1697645004000},"page":"736-745","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Relationship Between Steroid Hormone Profile and Premenstrual Syndrome in Women Consulting for Infertility or Recurrent Miscarriage"],"prefix":"10.1007","volume":"31","author":[{"given":"Joseph V.","family":"Turner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas A.","family":"McLindon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien V.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolaine","family":"Alefsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9","family":"Ecochard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,18]]},"reference":[{"key":"1375_CR1","doi-asserted-by":"crossref","unstructured":"Crowley SK, Girdler SS. Neurosteroid, GABAergic and hypothalamic pituitary adrenal (HPA) axis regulation: what is the current state of knowledge in humans? Psychopharmacology (Berl). 2014;231(17):3619\u201334. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24756763","DOI":"10.1007\/s00213-014-3572-8"},{"key":"1375_CR2","doi-asserted-by":"crossref","unstructured":"B\u00e4ckstr\u00f6m T, Bixo M, Str\u00f6mberg J. GABAA receptor-modulating steroids in relation to women\u2019s behavioral health. Curr Psychiatry Rep. 2015;17(11):92. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26396092","DOI":"10.1007\/s11920-015-0627-4"},{"key":"1375_CR3","doi-asserted-by":"crossref","unstructured":"Schmidt PJ, Purdy RH, Moore PH, Jr., et al. Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J Clin Endocrinol Metab. 1994;79(5):1256\u201360. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7962316","DOI":"10.1210\/jc.79.5.1256"},{"key":"1375_CR4","doi-asserted-by":"crossref","unstructured":"Van Goozen SH, Wiegant VM, Endert E, et al. Psychoendocrinological assessment of the menstrual cycle: the relationship between hormones, sexuality, and mood. Arch Sex Behav. 1997;26(4):359\u201382. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9251835","DOI":"10.1023\/A:1024587217927"},{"key":"1375_CR5","doi-asserted-by":"crossref","unstructured":"B\u00e4ckstr\u00f6m T, Sanders D, Leask R, et al. Mood, sexuality, hormones, and the menstrual cycle. II. Hormone levels and their relationship to the premenstrual syndrome. Psychosom Med. 1983;45(6):503\u20137. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/6686333","DOI":"10.1097\/00006842-198312000-00004"},{"key":"1375_CR6","doi-asserted-by":"crossref","unstructured":"Girdler SS, Straneva PA, Light KC, et al. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry. 2001;49(9):788\u201397. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11331087","DOI":"10.1016\/S0006-3223(00)01044-1"},{"key":"1375_CR7","doi-asserted-by":"crossref","unstructured":"Hammarb\u00e4ck S, Damber JE, B\u00e4ckstr\u00f6m T. Relationship between symptom severity and hormone changes in women with premenstrual syndrome. J Clin Endocrinol Metab. 1989;68(1):125\u201330. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/2491857","DOI":"10.1210\/jcem-68-1-125"},{"key":"1375_CR8","doi-asserted-by":"crossref","unstructured":"Hsiao CC, Liu CY, Hsiao MC. No correlation of depression and anxiety to plasma estrogen and progesterone levels in patients with premenstrual dysphoric disorder. Psychiatry Clin Neurosci. 2004;58(6):593\u20139. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15601382","DOI":"10.1111\/j.1440-1819.2004.01308.x"},{"key":"1375_CR9","doi-asserted-by":"crossref","unstructured":"Lovick TA, Guapo VG, Anselmo-Franci JA, et al. A specific profile of luteal phase progesterone is associated with the development of premenstrual symptoms. Psychoneuroendocrinology. 2017;75:83\u201390. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27810707","DOI":"10.1016\/j.psyneuen.2016.10.024"},{"key":"1375_CR10","doi-asserted-by":"crossref","unstructured":"Redei E, Freeman EW. Preliminary evidence for plasma adrenocorticotropin levels as biological correlates of premenstrual symptoms. Acta Endocrinol (Copenh). 1993;128(6):536\u201342. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8393259","DOI":"10.1530\/acta.0.1280536"},{"key":"1375_CR11","doi-asserted-by":"crossref","unstructured":"Rubinow DR, Hoban MC, Grover GN, et al. Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects. Am J Obstet Gynecol. 1988;158(1):5\u201311. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/2962499","DOI":"10.1016\/0002-9378(88)90765-X"},{"key":"1375_CR12","doi-asserted-by":"crossref","unstructured":"Watts JF, Butt WR, Logan Edwards R, et al. Hormonal studies in women with premenstrual tension. Br J Obstet Gynaecol. 1985;92(3):247\u201355. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/4038882","DOI":"10.1111\/j.1471-0528.1985.tb01090.x"},{"key":"1375_CR13","doi-asserted-by":"crossref","unstructured":"B\u00e4ckstr\u00f6m T, Bixo M, Johansson M, et al. Allopregnanolone and mood disorders. Prog Neurobiol. 2014;113:88\u201394. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23978486","DOI":"10.1016\/j.pneurobio.2013.07.005"},{"key":"1375_CR14","doi-asserted-by":"crossref","unstructured":"Di Florio A, Alexander D, Schmidt PJ, et al. Progesterone and plasma metabolites in women with and in those without premenstrual dysphoric disorder. Depress Anxiety. 2018;35(12):1168\u20131177. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30184299","DOI":"10.1002\/da.22827"},{"key":"1375_CR15","doi-asserted-by":"crossref","unstructured":"Ecochard R, Duterque O, Leiva R, et al. Self-identification of the clinical fertile window and the ovulation period. Fertil Steril. 2015;103(5):1319\u201325.e3. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25724738","DOI":"10.1016\/j.fertnstert.2015.01.031"},{"key":"1375_CR16","doi-asserted-by":"crossref","unstructured":"Billings EL, Brown JB, Billings JJ, et al. Symptoms and hormonal changes accompanying ovulation. Lancet. 1972;1(7745):282\u20134. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/4109930","DOI":"10.1016\/S0140-6736(72)90291-7"},{"key":"1375_CR17","doi-asserted-by":"crossref","unstructured":"Ecochard R, Boehringer H, Rabilloud M, et al. Chronological aspects of ultrasonic, hormonal, and other indirect indices of ovulation. BJOG. 2001;108(8):822\u20139. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11510707","DOI":"10.1111\/j.1471-0528.2001.00194.x"},{"key":"1375_CR18","doi-asserted-by":"crossref","unstructured":"Vigil P, Lyon C, Flores B, et al. Ovulation, a sign of health. Linacre Q. 2017;84(4):343\u2013355. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29255329","DOI":"10.1080\/00243639.2017.1394053"},{"key":"1375_CR19","unstructured":"Hilgers TW, Daly KD, Prebil AM, et al. Cumulative pregnancy rates in patients with apparently normal fertility and fertility-focused intercourse. J Reprod Med. 1992;37(10):864\u20136. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1479570"},{"key":"1375_CR20","unstructured":"Hilgers TW, Stanford JB. Creighton Model NaProEducation Technology for avoiding pregnancy. Use effectiveness. J Reprod Med. 1998;43(6):495\u2013502. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9653695"},{"key":"1375_CR21","first-page":"509","volume-title":"The Medical and Surgical Practice of NaProTECHNOLOGY","author":"TW Hilgers","year":"2004","unstructured":"Hilgers TW. NaProTECHNOLOGY in infertility: evaluation and treatment. In: Hilgers TW (ed) The Medical and Surgical Practice of NaProTECHNOLOGY. Omaha: Pope Paul VI Institute Press; 2004. p. 509\u201340."},{"key":"1375_CR22","doi-asserted-by":"crossref","unstructured":"Reid RL, Soares CN. Premenstrual dysphoric disorder: contemporary diagnosis and management. J Obstet Gynaecol Can. 2018;40(2):215\u2013223. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29132964","DOI":"10.1016\/j.jogc.2017.05.018"},{"key":"1375_CR23","doi-asserted-by":"crossref","unstructured":"Frank-Herrmann P, Heil J, Gnoth C, et al. The effectiveness of a fertility awareness based method to avoid pregnancy in relation to a couple\u2019s sexual behaviour during the fertile time: a prospective longitudinal study. Hum Reprod. 2007;22(5):1310\u20139. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17314078","DOI":"10.1093\/humrep\/dem003"},{"key":"1375_CR24","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Depressive disorders. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. 2013. p. 171\u2013175.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"1375_CR25","unstructured":"Hilgers TW, Abraham GE, Cavanagh D. Natural family planning. I. The peak symptom and estimated time of ovulation. Obstet Gynecol. 1978;52(5):575\u201382. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/724176"},{"key":"1375_CR26","doi-asserted-by":"crossref","unstructured":"Abdullah S, Bouchard T, Leiva R, et al. Distinct urinary progesterone metabolite profiles during the luteal phase. Horm Mol Biol Clin Investig. 2022;44(2):137\u2013144. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36578213","DOI":"10.1515\/hmbci-2022-0065"},{"key":"1375_CR27","doi-asserted-by":"publisher","unstructured":"Yonkers KA, O'Brien PM, Eriksson E. Premenstrual syndrome. Lancet. 2008;371(9619):1200\u201310. https:\/\/doi.org\/10.1016\/S0140-6736(08)60527-9.","DOI":"10.1016\/S0140-6736(08)60527-9"},{"key":"1375_CR28","doi-asserted-by":"crossref","unstructured":"Vanselow W, Dennerstein L, Greenwood KM, et al. Effect of progesterone and its 5 alpha and 5 beta metabolites on symptoms of premenstrual syndrome according to route of administration. J Psychosom Obstet Gynaecol. 1996;17(1):29\u201338. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8860884","DOI":"10.3109\/01674829609025661"},{"key":"1375_CR29","unstructured":"Magill PJ. Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome. Progesterone Study Group. Br J Gen Pract. 1995;45(400):589\u201393. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8554838"},{"key":"1375_CR30","doi-asserted-by":"crossref","unstructured":"Ford O, Lethaby A, Roberts H, et al. Progesterone for premenstrual syndrome. Cochrane Database Syst Rev. 2012;2012(3):CD003415. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22419287","DOI":"10.1002\/14651858.CD003415.pub4"},{"key":"1375_CR31","doi-asserted-by":"crossref","unstructured":"Rapkin AJ, Morgan M, Goldman L, et al. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol. 1997;90(5):709\u201314. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9351749","DOI":"10.1016\/S0029-7844(97)00417-1"},{"key":"1375_CR32","doi-asserted-by":"crossref","unstructured":"Timby E, B\u00e4ckstr\u00f6m T, Nyberg S, et al. Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls-a pilot study. Psychopharmacology (Berl). 2016;233(11):2109\u20132117. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26960697","DOI":"10.1007\/s00213-016-4258-1"},{"key":"1375_CR33","doi-asserted-by":"crossref","unstructured":"Sundstr\u00f6m Poromaa I, Smith S, Gulinello M. GABA receptors, progesterone and premenstrual dysphoric disorder. Arch Womens Ment Health. 2003;6(1):23\u201341. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12715262","DOI":"10.1007\/s00737-002-0147-1"},{"key":"1375_CR34","doi-asserted-by":"crossref","unstructured":"Cunningham J, Yonkers KA, O\u2019Brien S, et al. Update on research and treatment of premenstrual dysphoric disorder. Harv Rev Psychiatry. 2009;17(2):120\u201337. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19373620","DOI":"10.1080\/10673220902891836"},{"key":"1375_CR35","doi-asserted-by":"crossref","unstructured":"Facchinetti F, Martignoni E, Petraglia F, et al. Premenstrual fall of plasma beta-endorphin in patients with premenstrual syndrome. Fertil Steril. 1987;47(4):570\u20133. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/2952525","DOI":"10.1016\/S0015-0282(16)59104-3"},{"key":"1375_CR36","first-page":"345","volume-title":"The medical and surgical practice of NaProTECHNOLOGY","author":"TW Hilgers","year":"2004","unstructured":"Hilgers TW. Premenstrual syndrome: evaluation and treatment. In: Hilgers TW (ed) The medical and surgical practice of NaProTECHNOLOGY. Omaha: Pope Paul VI Institute Press; 2004. p. 345\u201368."}],"container-title":["Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-023-01375-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43032-023-01375-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-023-01375-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T19:21:09Z","timestamp":1709580069000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43032-023-01375-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,18]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1375"],"URL":"https:\/\/doi.org\/10.1007\/s43032-023-01375-w","relation":{},"ISSN":["1933-7191","1933-7205"],"issn-type":[{"type":"print","value":"1933-7191"},{"type":"electronic","value":"1933-7205"}],"subject":[],"published":{"date-parts":[[2023,10,18]]},"assertion":[{"value":"21 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. Data was collected with approval from the Mater Misericordiae Human Research Ethics Committee (approval number: ERM 72620, amendment AM\/MML\/72620 V1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Lucas McLindon has been principal investigator in non-sponsored trials of progesterone (Perrigo product) use in early pregnancy. The other authors declare no other interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}